Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease

Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and... This narrative review summarizes findings from recent randomized clinical trials of glucagon-like peptide 1 receptor agonists and compares this therapy with sodium-glucose cotransporter 2 inhibitors and other interventions for reducing major adverse events for patients with type 2 diabetes and atherosclerotic cardiovascular disease. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease

Loading next page...
 
/lp/american-medical-association/use-of-glucagon-like-peptide-1-receptor-agonists-in-patients-with-type-fnhU5P4DKp
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2020.1966
Publisher site
See Article on Publisher Site

Abstract

This narrative review summarizes findings from recent randomized clinical trials of glucagon-like peptide 1 receptor agonists and compares this therapy with sodium-glucose cotransporter 2 inhibitors and other interventions for reducing major adverse events for patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Journal

JAMA CardiologyAmerican Medical Association

Published: Oct 17, 2020

References